Metastatic bone disease in the era of bone-targeted therapy: clinical impact

摘要: Advances in the diagnosis and treatment of tumors by surgery, chemotherapy, biotherapy, radiotherapy other modalities have increased survival cancer patients over last 20 years. As a consequence, bone now represents third most common site metastatic involvement after lung liver. Approximately 20-25% with neoplastic disease develop clinically evident metastases (BMs) during natural course their illness, further 50% such lesions being identified autopsy. BMs are major cause morbidity because epidemiological clinical impact. Pain is frequent symptom about 75% but serious complications can also occur, as pathological fractures, spinal cord compression, hypercalcemia marrow suppression. These worsen patient's general condition reduce patients' mobility, facilitating development infections, skin ulcers, deep vein thrombosis, etc., ultimately reducing prognosis quality life. The frequency depends on type administered. Over 10 years, introduction bisphosphonates for has led to marked decrease complications, thus improving life outcome. Furthermore, progress understanding pathophysiology resulted new bone-targeted molecules denosumab. We therefore felt it would be useful report epidemiological, economic impact setting.